Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Current Deferred Revenue (2018 - 2026)

TransMedics has reported Current Deferred Revenue over the past 8 years, most recently at $2.9 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 66.76% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, up 66.76%, while the annual FY2025 figure was $2.9 million, 66.76% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $2.9 million at TransMedics, down from $3.3 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $3.3 million in Q3 2025 and troughed at $152000.0 in Q3 2021.
  • A 5-year average of $1.2 million and a median of $960000.0 in 2021 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: crashed 49.68% in 2022 and later soared 1063.27% in 2023.
  • Year by year, Current Deferred Revenue stood at $250000.0 in 2021, then fell by 3.6% to $241000.0 in 2022, then surged by 713.69% to $2.0 million in 2023, then decreased by 11.17% to $1.7 million in 2024, then surged by 66.76% to $2.9 million in 2025.
  • Business Quant data shows Current Deferred Revenue for TMDX at $2.9 million in Q4 2025, $3.3 million in Q3 2025, and $1.6 million in Q2 2025.